Postural orthostatic tachycardia with chronic fatigue after HPV vaccination as part of the “Autoimmune/auto-inflammatory syndrome induced by adjuvants”: Case report and literature review

Journal of Investigative Medicine High Impact Case Reports

Volumn 2, Issue 1, 2014, Pages

  Tomljenovic, Lucija ^a,b   Colafrancesco, Serena ^a,c   Perricone, Carlo ^a,c   Shoenfeld, Yehuda ^a,d  

^a SHEBA MEDICAL CENTER   (Israel)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

ASIA syndrome; Autoantibodies; Autoimmunity; Chronic fatigue; Gardasil; HPV vaccine; Postural orthostatic tachycardia; Vaccine adjuvants

Indexed keywords

EID: 84945119848     PISSN: None     EISSN: 23247096     Source Type: Journal    
DOI: 10.1177/2324709614527812     Document Type: Review

References (54)

1. Grubb BP, Kanjwal Y, Kosinski DJ. The postural tachycardia syndrome: a concise guide to diagnosis and management. J Cardiovasc Electrophysiol. 2006;17:108-112.
2. Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol. 2009;20: 352-358.
3. Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: the Mayo Clinic experience. Mayo Clin Proc. 2007;82:308-313.
4. Schondorf R, Benoit J, Wein T, Phaneuf D. Orthostatic intolerance in the chronic fatigue syndrome. J Auton Nerv Syst. 1999;75:192-201.
5. Schondorf R, Freeman R. The importance of orthostatic intolerance in the chronic fatigue syndrome. Am J Med Sci. 1999;317:117-123.
6. Hoad A, Spickett G, Elliott J, Newton J. Postural orthostatic tachycardia syndrome is an under-recognized condition in chronic fatigue syndrome. QJM. 2008;101:961-965.
7. Okamoto LE, Raj SR, Peltier A, et al. Neurohumoral and haemodynamic profile in postural tachycardia and chronic fatigue syndromes. Clin Sci (Lond). 2012;122:183-192.
8. Stewart JM, Gewitz MH, Weldon A, Munoz J. Patterns of orthostatic intolerance: the orthostatic tachycardia syndrome and adolescent chronic fatigue. J Pediatr. 1999;135(2 pt 1):218-225.
9. Authier FJ, Sauvat S, Champey J, Drogou I, Coquet M, Gherardi RK. Chronic fatigue syndrome in patients with macrophagic myofasciitis. Arthritis Rheum. 2003;48:569-570.
10. Rosenblum H, Shoenfeld Y, Amital H. The common immuno-genic etiology of chronic fatigue syndrome: from infections to vaccines via adjuvants to the ASIA syndrome. Infect Dis Clin North Am. 2011;25:851-863.
11. Mosnaim AD, Abiola R, Wolf ME, Perlmuter LC. Etiology and risk factors for developing orthostatic hypotension. Am J Ther. 2009;17:86-91.
12. Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol. 2014;21:135-139..
13. Tsai CK, Chu H, Cheng CA. Novel H1N1 influenza vaccine the cause of postural orthostatic tachycardia syndrome followed by cerebral hypoperfusion. J Med Sci. 2011;31:91-93.
14. Agmon-Levin N, Shoenfeld Y. Chronic fatigue syndrome with autoantibodies—the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev. 2008;8:52-55.
15. Exley C, Swarbrick L, Gherardi RK, Authier FJ. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med Hypotheses. 2009;72:135-139.
16. Nishikai M, Tomomatsu S, Hankins RW, et al. Autoantibodies to a 68/48 kDa protein in chronic fatigue syndrome and primary fibromyalgia: a possible marker for hypersomnia and cognitive disorders. Rheumatology (Oxford). 2001;40:806-810.
17. Wang XL, Chai Q, Charlesworth MC, et al. Autoimmunoreactive IgGs from patients with postural orthostatic tachycardia syndrome. Proteomics Clin Appl. 2012;6:615-625.
18. Morris G, Berk M, Galecki P, Maes M. The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs) [published online September 26, 2013]. Mol Neurobiol. doi:10.1007/s12035-013-8553-0.
19. Kanjwal K, Karabin B, Kanjwal Y, Grubb BP. Autonomic dysfunction presenting as postural orthostatic tachycardia syndrome in patients with multiple sclerosis. Int J Med Sci. 2010;7:62-67.
20. Calabrese LH, Davis ME, Wilke WS. Chronic fatigue syndrome and a disorder resembling Sjorgen’s syndrome: preliminary report. Clin Infect Dis. 1994;18(suppl 1):S28-S31.
21. Tang S, Calkins H, Petri M. Neurally mediated hypotension in systemic lupus erythematosus patients with fibromyalgia. Rheumatology (Oxford). 2004;43:609-614.
22. Mallipeddi R, Mathias CJ. Raynaud’s phenomenon after sympathetic denervation in patients with primary autonomic failure: questionnaire survey. BMJ. 1998;316:438-439.
23. Andrews N, Stowe J, Al-Shahi Salman R, Miller E. Guillain-Barre syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series. Vaccine. 2011;29:7878-7882.
24. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-1533.
25. Gherardi R, Authier F. Macrophagic myofasciitis: characterization and pathophysiology. Lupus. 2012;21:184-189.
26. Gherardi RK, Authier FJ. Aluminum inclusion macrophagic myofasciitis: a recently identified condition. Immunol Allergy Clin North Am. 2003;23:699-712.
27. Tomljenovic L, Shoenfeld Y. Association between vaccination and Guillain-Barre syndrome. Lancet Infect Dis. 2013;13: 730-731.
28. Poser CM, Behan PO. Late onset of Guillain-Barre syndrome. J Neuroimmunol. 1982;3:27-41.
29. Shoenfeld Y, Agmon-Levin N. “ASIA”—autoimmune/ inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4-8.
30. Zafrir Y, Agmon-Levin N, Paz Z, Shilton T, Shoenfeld Y. Autoimmunity following hepatitis B vaccine as part of the spectrum of “Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants” (ASIA): analysis of 93 cases. Lupus. 2012;21:146-152.
31. Gatto M, Agmon-Levin N, Soriano A, et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol. 2013;32:1301-1307.
32. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302:750-757.
33. US Centers for Disease Control and Prevention. The Vaccine Adverse Event Reporting System (VAERS). http://wonder. cdc.gov/vaers.html. Accessed February 28, 2014.
34. Tomljenovic L, Shaw CA. Too fast or not too fast: the FDA’s approval of Merck’s HPV vaccine Gardasil. J Law Med Ethics. 2012;40:673-681.
35. Tomljenovic L, Shaw CA. Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds? Ann Med. 2013;45:182-193.
36. Carruthers BM, van de Sande MI, De Meirleir KL, et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med. 2011;270:327-338.
37. Batista-Duharte A, Lindblad EB, Oviedo-Orta E. Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol Lett. 2011;203:97-105.
38. Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009;5:648-652.
39. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009;18:1217-1225.
40. Gherardi RK. Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome. Rev Neurol (Paris). 2003;159:162-164.
41. Tomljenovic L, Spinosa JP, Shaw CA. Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe? Curr Pharm Des. 2013;19:1466-1487.
42. Passeri E, Villa C, Couette M, et al. Long-term follow-up of cognitive dysfunction in patients with aluminum hydroxide-induced macrophagic myofasciitis (MMF). J Inorg Biochem. 2011;105:1457-1463.
43. Couette M, Boisse MF, Maison P, et al. Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction. J Inorg Biochem. 2009;103:1571-1578.
44. Lujan L, Perez M, Salazar E, et al. Autoimmune/autoinflam-matory syndrome induced by adjuvants (ASIA syndrome) in commercial sheep. Immunol Res. 2013;56:317-324.
45. Petrik MS, Wong MC, Tabata RC, Garry RF, Shaw CA. Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice. Neuromolecular Med. 2007;9:83-100.
46. Shoenfeld Y. HPV vaccines and autoimmune diseases. J Intern Med. 2012;272:98.
47. Tomljenovic L, Shaw CA. No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil? J Intern Med. 2012;272:514-515.
48. Sutton I, Lahoria R, Tan IL, Clouston P, Barnett MH. CNS demyelination and quadrivalent HPV vaccination. Mult Scler. 2009;15:116-119.
49. Chang J, Campagnolo D, Vollmer TL, Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry. 2011;82:1296-1298.
50. Lee SH. Detection of human papillomavirus L1 gene DNA fragments in postmortem blood and spleen after Gardasil vacci-nation—a case report. Adv Biosci Biotech. 2012;3:1214-1224.
51. Colafrancesco S, Perricone C, Tomljenovic L, Shoenfeld Y. HPV vaccines and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol. 2013;70:309-316.
52. DiMario FJ Jr, Hajjar M, Ciesielski T. A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus. J Child Neurol. 2010;25:321-327.
53. Tomljenovic L, Shaw CA. Who profits from uncritical acceptance of biased estimates of vaccine efficacy and safety? Am J Public Health. 2012;102(9):e13-e14.
54. Zivkovic I, Petrusic V, Stojanovic M, Inic-Kanada A, Stojicevic I, Dimitrijevic L. Induction of decreased fecundity by tetanus toxoid hyper-immunization in C57BL/6 mice depends on the applied adjuvant. Innate Immun. 2012;18:333-342.